breast cancer, lung adenocarcinoma, prostate cancer, cervical cancer, ovarian cancer
Conditions
Interventions
Gold Standard:pathological diagnosis
Index test:Trop-2 targeted PET/MR or PET/CT
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.The participant or their legal representative must be able to sign and date the informed consent form. 2.The participant must agree to comply with the study procedures and cooperate throughout the entire research process. 3.Adult patients or healthy volunteers (aged 18 years or older), regardless of gender. 4.Patients clinically suspected or diagnosed with malignant tumors such as pancreatic cancer, ovarian cancer, or lung adenocarcinoma (supported by evidence including serum tumor markers, ultrasound, CT, MRI imaging data, and histopathological examination), and in generally good health. 5.Meet specific laboratory test results. 6.Women of childbearing potential must have used contraception for at least one month prior to screening and commit to using effective contraception throughout the study period and for a specified time after the study ends. 7.Other predefined inclusion criteria.
Exclusion criteria
Exclusion criteria: 1.Those who are unable to complete a PET/MR or PET/CT examination (including inability to lie down, claustrophobia, radiophobia, etc.); 2.Having other comorbidities; 3.Patients with known hypersensitivity to Trop-2 antibody fragment developers or synthetic excipients; fasting blood glucose level greater than 11.0 mmol/L prior to 18F-FDG injection; 4.Have a history of comorbid drug use; 5.Patients considered by the investigator to have poor compliance; 6.Patients during pregnancy or lactation; 7.Persons with other factors that make participation in this test inappropriate;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Standardized uptake values assessment of region of interest;Accuracy;Sensitivity;Specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood test, urine test,liver and kidney function and other biochemical indicators;electrocardiography,ECG;Radioactivity in the blood and urine samples;Pathological sections of tumour tissue; | — |
Countries
China
Contacts
Public ContactXiaoli Lan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed